Ad is loading...
ASVHX
Price
$11.67
Change
-$0.08 (-0.68%)
Updated
Nov 15 closing price
VISVX
Price
$49.63
Change
-$0.34 (-0.68%)
Updated
Nov 15 closing price
Ad is loading...

ASVHX vs VISVX

Header iconASVHX vs VISVX Comparison
Open Charts ASVHX vs VISVXBanner chart's image
American Century Small Cap Value G
Price$11.67
Change-$0.08 (-0.68%)
VolumeN/A
CapitalizationN/A
Vanguard Small Cap Value Index I
Price$49.63
Change-$0.34 (-0.68%)
VolumeN/A
CapitalizationN/A
ASVHX vs VISVX Comparison Chart
Loading...
View a ticker or compare two or three
VS
ASVHX vs. VISVX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASVHX is a Buy and VISVX is a Buy.

FUNDAMENTALS
Fundamentals
VISVX has more cash in the bank: 57.6B vs. ASVHX (5.77B). VISVX (1.90) and ASVHX (1.86) have matching dividends . ASVHX was incepted earlier than VISVX: ASVHX (6 years) vs VISVX (27 years). ASVHX is a more actively managed with annual turnover of: 44.00 vs. VISVX (16.00). ASVHX has a lower initial minimum investment than VISVX: ASVHX (0) vs VISVX (3000). VISVX (28.71) and ASVHX (27.96) have marching annual gain over last year. ASVHX return over 5 years is better than : 61.53 vs. VISVX (57.32).
ASVHXVISVXASVHX / VISVX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence6 years27 years-
Gain YTD12.45715.43381%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets5.77B57.6B10%
Annual Yield % from dividends1.861.9098%
Returns for 1 year27.9628.7197%
Returns for 3 years0.9813.237%
Returns for 5 years61.5357.32107%
Returns for 10 yearsN/A108.21-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DX12.420.04
+0.32%
Dynex Capital
PNR105.920.06
+0.06%
Pentair plc
TGNA17.64-0.47
-2.60%
TEGNA
HCTI1.16-0.04
-3.33%
Healthcare Triangle
ATOS1.28-0.09
-6.57%
Atossa Therapeutics